Next earnings date: 3 Sep 2025
KalVista Pharmaceuticals, Inc. – NASDAQ:KALV
KalVista Pharmaceuticals stock price today
$12.81
+4.28
+50.18%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 1 hour
KalVista Pharmaceuticals stock price monthly change
-34.59%
month
KalVista Pharmaceuticals stock price quarterly change
-34.59%
quarter
KalVista Pharmaceuticals stock price yearly change
-29.15%
year
KalVista Pharmaceuticals key metrics
Market Cap | 407.26M |
Enterprise value | 162.94M |
P/E | -2.31 |
EV/Sales | N/A |
EV/EBITDA | -1.84 |
Price/Sales | N/A |
Price/Book | 1.29 |
PEG ratio | 0.05 |
EPS | -3.54 |
Revenue | N/A |
EBITDA | -140.58M |
Income | -128.04M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeKalVista Pharmaceuticals stock price history
KalVista Pharmaceuticals stock forecast
KalVista Pharmaceuticals financial statements
Average Price Target
$22.67
Potential upside: 76.94%
Analysts Price target
Financials & Ratios estimates
| Jan 2023 | 0 | -14.33M | |
|---|---|---|---|
| Apr 2023 | 0 | -40.03M | |
| Jan 2024 | 0 | -29.02M | |
| Apr 2024 | 1.20M | -44.65M | -3702.32% |
| 2024-09-05 | -0.95 | -0.87 |
|---|---|---|
| 2024-12-05 | -0.91 | -0.91 |
| Jan 2023 | 203468000 | 19.02M | 9.35% |
|---|---|---|---|
| Apr 2023 | 183202000 | 22.17M | 12.11% |
| Jan 2024 | 113968000 | 25.38M | 22.27% |
| Apr 2024 | 235404000 | 28.82M | 12.24% |
| Jan 2023 | -9.28M | -2.51M | 57.81M |
|---|---|---|---|
| Apr 2023 | -22.63M | -6.21M | -33K |
| Jan 2024 | -27.57M | -6.70M | 284K |
| Apr 2024 | -15.10M | -126.18M | 150.09M |
KalVista Pharmaceuticals alternative data
| Sep 2023 | 118 |
|---|---|
| Oct 2023 | 118 |
| Nov 2023 | 118 |
| Dec 2023 | 118 |
| Jan 2024 | 118 |
| Feb 2024 | 118 |
| Mar 2024 | 118 |
| Apr 2024 | 118 |
| May 2024 | 118 |
| Jun 2024 | 118 |
| Jul 2024 | 118 |
KalVista Pharmaceuticals other data
99.38%
+2.06%
of KALV is owned by hedge funds
83
-12
24.32M
+544.11K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 576768 | 40000 |
| Feb 2024 | 741786 | 279594 |
| May 2024 | 0 | 54832 |
| Jun 2024 | 0 | 7465 |
| Aug 2024 | 0 | 33341 |
| Sep 2024 | 0 | 7352 |
| Nov 2024 | 0 | 33819 |
| Dec 2024 | 0 | 7627 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | PALLEIKO BENJAMIN L director, officer.. | Common Stock | 7,627 | $9.75 | $74,363 | ||
Option | PALLEIKO BENJAMIN L director, officer.. | Common Stock | 15,625 | N/A | N/A | ||
Option | PALLEIKO BENJAMIN L director, officer.. | Restricted Stock Unit | 15,625 | N/A | N/A | ||
Sale | AUDHYA PAUL K. officer: CHIEF MEDICAL OFFICER | Common Stock | 2,187 | $9.87 | $21,586 | ||
Sale | YEA CHRISTOPHER officer: CHIEF DE.. | Common Stock | 1,963 | $9.87 | $19,379 | ||
Option | AUDHYA PAUL K. officer: CHIEF MEDICAL OFFICER | Common Stock | 5,000 | N/A | N/A | ||
Option | AUDHYA PAUL K. officer: CHIEF MEDICAL OFFICER | Restricted Stock Unit | 5,000 | N/A | N/A | ||
Option | YEA CHRISTOPHER officer: CHIEF DE.. | Common Stock | 3,125 | N/A | N/A | ||
Option | YEA CHRISTOPHER officer: CHIEF DE.. | Restricted Stock Unit | 3,125 | N/A | N/A | ||
Sale | PALLEIKO BENJAMIN L director, officer.. | Common Stock | 14,400 | $9.26 | $133,301 |
| Insider | Compensation |
|---|---|
Mr. Thomas Andrew Crockett M.B.A. (1975) Chief Executive Officer & Director | $1,030,000 |
| Mr. Benjamin L. Palleiko (1966) Chief Bus. Officer & Chief Financial Officer | $711,850 |
| Dr. Christopher M. Yea Ph.D. (1964) Chief Devel. Officer | $697,340 |
KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning
KalVista: Poised For Rare Disease Transformation
KalVista: Potential First With Multiple Sebetralstat Regulatory Reviews In 2025
Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 Launch
KalVista: On Demand Oral Treatment For HAE Signifies Differentiated Advancement
KalVista's Sebetralstat: A Pill Worth Swallowing In HAE
BioCryst Is Not Currently Uncovering The Full Value Of ORLADEYO
KalVista Pharmaceuticals: The Share Price Rally Requires An Adjustment Of My Investment Thesis
KalVista: Another Setback But The Key Value Driver Is Still In Place
-
What's the price of KalVista Pharmaceuticals stock today?
One share of KalVista Pharmaceuticals stock can currently be purchased for approximately $12.81.
-
When is KalVista Pharmaceuticals's next earnings date?
KalVista Pharmaceuticals, Inc. is estimated to report earnings on Wednesday, 3 Sep 2025.
-
Does KalVista Pharmaceuticals pay dividends?
No, KalVista Pharmaceuticals does not pay dividends.
-
How much money does KalVista Pharmaceuticals make?
KalVista Pharmaceuticals has a market capitalization of 407.26M. KalVista Pharmaceuticals made a loss 126.64M US dollars in net income (profit) last year or -$0.91 on an earnings per share basis.
-
What is KalVista Pharmaceuticals's stock symbol?
KalVista Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "KALV".
-
What is KalVista Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of KalVista Pharmaceuticals?
Shares of KalVista Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are KalVista Pharmaceuticals's key executives?
KalVista Pharmaceuticals's management team includes the following people:
- Mr. Thomas Andrew Crockett M.B.A. Chief Executive Officer & Director(age: 50, pay: $1,030,000)
- Mr. Benjamin L. Palleiko Chief Bus. Officer & Chief Financial Officer(age: 59, pay: $711,850)
- Dr. Christopher M. Yea Ph.D. Chief Devel. Officer(age: 61, pay: $697,340)
-
How many employees does KalVista Pharmaceuticals have?
As Jul 2024, KalVista Pharmaceuticals employs 118 workers.
-
When KalVista Pharmaceuticals went public?
KalVista Pharmaceuticals, Inc. is publicly traded company for more then 10 years since IPO on 9 Apr 2015.
-
What is KalVista Pharmaceuticals's official website?
The official website for KalVista Pharmaceuticals is kalvista.com.
-
Where are KalVista Pharmaceuticals's headquarters?
KalVista Pharmaceuticals is headquartered at 55 Cambridge Parkway, Cambridge, MA.
-
How can i contact KalVista Pharmaceuticals?
KalVista Pharmaceuticals's mailing address is 55 Cambridge Parkway, Cambridge, MA and company can be reached via phone at 857 999 0075.
-
What is KalVista Pharmaceuticals stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for KalVista Pharmaceuticals in the last 12 months, the avarage price target is $22.67. The average price target represents a 76.94% change from the last price of $12.81.
KalVista Pharmaceuticals company profile:
KalVista Pharmaceuticals, Inc.
kalvista.comExchange:
NASDAQ
Full time employees:
150
Industry:
Biotechnology
Sector:
Healthcare
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
55 Cambridge Parkway
Cambridge, MA 02142
Cambridge, MA 02142
CIK: 0001348911
ISIN: US4834971032
CUSIP: 483497103
